A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT03800836 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Ipatasertib
DRUG: Paclitaxel
DRUG: Atezolizumab
DRUG: Nab-Paclitaxel
DRUG: AC

Sponsor

Hoffmann-La Roche